Razuprotafib - EyePoint Pharmaceuticals
Alternative Names: AKB-9778; EYP-2301Latest Information Update: 02 Apr 2025
At a glance
- Originator Procter & Gamble
- Developer Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; Medical Technology Enterprise Consortium; New York University; Quantum Leap Healthcare Collaborative; Whitehawk Therapeutics
- Class Amides; Antineoplastics; Carbamates; Eye disorder therapies; Small molecules; Sulfonic acids; Thiazoles; Thiophenes
- Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Diabetic retinopathy; Ocular hypertension; Open-angle glaucoma; Retinal vein occlusion; SARS-CoV-2 acute respiratory disease
- No development reported Age-related macular degeneration; Breast cancer